Interferon News and Research

RSS

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

New drug can prevent exacerbations of asthma due to common cold: Trial report

For the tens of thousands of asthma sufferers in the UK there is a “breakthrough” drug that reduces complications caused by the common cold, it is claimed.

22 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Interferon beta-1a shows promise against MS

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

20 Apr 2012

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.

20 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.

19 Apr 2012

Key data from Boehringer Ingelheim's hepatitis C virus clinical trial programme

Key data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical trial programme, HCVerso, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities.

6 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

Researchers uncover mechanism that explains link between autoimmunity and atherosclerosis

Patients with autoimmune diseases often show a predisposition to develop "hardening of the arteries" or atherosclerosis. LMU researchers have now uncovered a mechanism that establishes a causal link between the two disorders.

5 Apr 2012

Scientists discover new anti-HCV antibodies

A team led by scientists at The Scripps Research Institute has found antibodies that can prevent infection from widely differing strains of hepatitis C virus (HCV) in cell culture and animal models.

4 Apr 2012

Study sheds light on cellular mechanisms involved in flu resistance

Scientists from the University of Utah School of Medicine have discovered that a mouse protein called IFITM3 contributes to the body's defense against some types of viral infections by binding to an enzyme responsible for regulating the pH of a cell's waste disposal system.

2 Apr 2012

STAT-1 and PLSCR-1 proteins could play a crucial role in breast cancer

At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells.

2 Apr 2012

CBSM intervention can alter tumor-promoting processes in women with breast cancer

A team of researchers led by Michael H. Antoni, director of the Center for Psycho-Oncology Research at the University of Miami (UM) has shown that a stress management program tailored to women with breast cancer can alter tumor-promoting processes at the molecular level. The new study recently published in the journal Biological Psychiatry is one of the first to link psychological intervention with genetic expression in cancer patients.

22 Mar 2012

CCN1 protein orchestrates cellular antiviral response in the extracellular matrix

Brain-tumor cells that are infected with a cancer-killing virus release a protein "alarm bell" that warns other tumor cells of the impending infection and enables them to mount a defense against the virus, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

16 Mar 2012

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

MedivirAB a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

13 Mar 2012

U-M to research into treatment for hepatitis C

The Greenview Foundation has announced a gift of $57,000 to the University of Michigan Health System to support research on a treatment for hepatitis C.

12 Mar 2012

Inhaled interferon-gamma may effectively treat IPF

Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery, a peer-reviewed journal from Mary Ann Liebert, Inc.

1 Mar 2012